Your browser doesn't support javascript.
loading
Similar Breast Cancer Risk in Women Older Than 65 Years Initiating Glargine, Detemir, and NPH Insulins.
Bradley, Marie C; Chillarige, Yoganand; Lee, Hana; Wu, Xiyuan; Parulekar, Shruti; Wernecke, Michael; Bright, Patricia; Soukup, Mat; MaCurdy, Thomas E; Kelman, Jeffrey A; Graham, David J.
Afiliación
  • Bradley MC; Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD marie.bradley@fda.hhs.gov.
  • Chillarige Y; Acumen LLC, Burlingame, CA.
  • Lee H; Office of Biostatistics, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD.
  • Wu X; Acumen LLC, Burlingame, CA.
  • Parulekar S; Acumen LLC, Burlingame, CA.
  • Wernecke M; Acumen LLC, Burlingame, CA.
  • Bright P; Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD.
  • Soukup M; Office of Biostatistics, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD.
  • MaCurdy TE; Acumen LLC, Burlingame, CA.
  • Kelman JA; Centers for Medicare & Medicaid Services, Washington, DC.
  • Graham DJ; Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD.
Diabetes Care ; 43(4): 785-792, 2020 04.
Article en En | MEDLINE | ID: mdl-32075848
OBJECTIVE: To assess whether initiation of insulin glargine (glargine), compared with initiation of NPH or insulin detemir (detemir), was associated with an increased risk of breast cancer in women with diabetes. RESEARCH DESIGN AND METHODS: This was a retrospective new-user cohort study of female Medicare beneficiaries aged ≥65 years initiating glargine (203,159), detemir (67,012), or NPH (47,388) from September 2006 to September 2015, with follow-up through May 2017. Weighted Cox proportional hazards regression was used to estimate hazard ratios (HRs) and 95% CIs for incidence of breast cancer according to ever use, cumulative duration of use, cumulative dose of insulin, length of follow-up time, and a combination of dose and length of follow-up time. RESULTS: Ever use of glargine was not associated with an increased risk of breast cancer compared with NPH (HR 0.97; 95% CI 0.88-1.06) or detemir (HR 0.98; 95% CI 0.92-1.05). No increased risk was seen with glargine use compared with either NPH or detemir by duration of insulin use, length of follow-up, or cumulative dose of insulin. No increased risk of breast cancer was observed in medium- or high-dose glargine users compared with low-dose users. CONCLUSIONS: Overall, glargine use was not associated with an increased risk of breast cancer compared with NPH or detemir in female Medicare beneficiaries.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Diabetes Mellitus Tipo 2 / Insulina Detemir / Insulina Glargina / Insulina Isófana Tipo de estudio: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Aged80 / Female / Humans País/Región como asunto: America do norte Idioma: En Revista: Diabetes Care Año: 2020 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Diabetes Mellitus Tipo 2 / Insulina Detemir / Insulina Glargina / Insulina Isófana Tipo de estudio: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Aged80 / Female / Humans País/Región como asunto: America do norte Idioma: En Revista: Diabetes Care Año: 2020 Tipo del documento: Article